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Abstract
Background: Central nervous system (CNS) infections are a significant contributor to morbidity and mortality
globally. However, most published studies have been conducted in developed countries where the epidemiology
and aetiology differ significantly from less developed areas. Additionally, there may be regional differences due to
variation in the socio-economic levels, public health services and vaccination policies. Currently, no prospective
studies have been conducted in Sabah, East Malaysia to define the epidemiology and aetiology of CNS infections. A
better understanding of these is essential for the development of local guidelines for diagnosis and management.
Methods: We conducted a prospective observational cohort study in patients aged 12 years and older with
suspected central nervous system infections at Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia between
February 2012 and March 2013. Cerebrospinal fluid was sent for microscopy, biochemistry, bacterial and
mycobacterial cultures, Mycobacterium tuberculosis polymerase chain reaction (PCR), and multiplex and MassCode
PCR for various viral and bacterial pathogens.
Results: A total of 84 patients with clinically suspected meningitis and encephalitis were enrolled. An aetiological
agent was confirmed in 37/84 (44 %) of the patients. The most common diagnoses were tuberculous meningitis
(TBM) (41/84, 48.8 %) and cryptococcal meningoencephalitis (14/84, 16.6 %). Mycobacterium tuberculosis was
confirmed in 13/41 (31.7 %) clinically diagnosed TBM patients by cerebrospinal fluid PCR or culture. The acute case
fatality rate during hospital admission was 16/84 (19 %) in all patients, 4/43 (9 %) in non-TBM, and 12/41 (29 %) in
TBM patients respectively (p = 0.02).
Conclusion: TBM is the most common cause of CNS infection in patients aged 12 years or older in Kota Kinabalu,
Sabah, Malaysia and is associated with high mortality and morbidity. Further studies are required to improve the
management and outcome of TBM.
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Background
Central nervous system (CNS) infections including men-
ingitis and encephalitis result in significant morbidity
and mortality in hospitalized patients [1–6]. The world-
wide incidence and reported aetiology of CNS infections
vary according to age, geographical region, economic
status, vaccination policies and diagnostic capacity.
Prospective studies in various countries conducted to
define the aetiology of CNS infections have shown con-
trasting results [1–6]. In an encephalitis study in Eng-
land, infections (42 %) were the leading aetiology,
followed by undetermined (37 %) and immune-mediated
causes (21 %) [3]. Among those with infectious enceph-
alitis, herpes simplex virus (19 %), varicella zoster virus
(5 %) and Mycobacterium tuberculosis (MTB) (5 %)
were the most common diagnoses [3]. In the California
Encephalitis Project, the frequency of autoimmune N-
methyl-D-aspartate receptor (anti-NMDAR) encephalitis
was four times that of viral aetiologies in a cohort of
young individuals [7]. In Vietnam, viral encephalitis and
meningitis accounted for 34 % of adult CNS infections,
with dengue (11 %), enteroviruses (10 %) and herpes sim-
plex (11 %) being the most commonly identified patho-
gens, while tuberculous meningitis (TBM) accounted for
14 % of cases [5]. Streptococcus pneumoniae and Neisseria
meningitides are the most common pathogens of bacterial
meningitis in developed countries, however Streptococcus
suis, a zoonotic pathogens from pigs, is the most common
cause in Vietnam [4, 5]. Taken together, these data suggest
that local data are required to develop clinically relevant
guidelines
In Malaysia, only confirmed cases of viral encephalitis
are notifiable while meningitis is not, requiring prospect-
ive studies to detail the epidemiology of CNS infections.
In Sarawak, East Malaysia, paediatric studies of CNS
Japanese encephalitis and human enterovirus 71 infec-
tions have been undertaken [8, 9]. However, no pro-
spective studies have been conducted in Malaysian
Borneo, to define the epidemiology and aetiology of
meningitis and encephalitis in adults. In anticipation of
future development of local clinical guidelines, we con-
ducted a prospective hospital-based study to evaluate
the aetiology and epidemiology of CNS infections in
Kota Kinabalu, Sabah, Malaysia.
Methods
Study site and design
This was a prospective observational cohort study con-
ducted at Queen Elizabeth Hospital, Kota Kinabalu,
Sabah, East Malaysia, an adult tertiary care hospital with
a catchment population of over 1 million. We screened
all inpatients with suspected meningitis or encephalitis
from February 2012 till March 2013. Research clinicians
used a standardised data sheet to collect demographic
data, epidemiological information, clinical history, vital
signs, physical observations, biochemical and microbio-
logical data, imaging reports, treatment, outcome, and
final diagnosis. The research team followed up patients
regularly until discharge or death. All patients were
managed according to Malaysian Ministry of Health
guidelines. For TBM, in addition to anti-tubercular medica-
tion, this included dexamethasone 0.3–0.4 mg/kg/day for
week 1, 0.2–0.3 mg/kg/day for week 2, 0.1–0.2 mg/kg/day
for week 3 and 0.1 mg/kg/day for week 4, followed by
4 weeks of dexamethasone decreasing by 1 mg each week.
Childhood vaccinations for potential CNS pathogens in
Sabah, Malaysia include diphtheria-pertussis-tetanus,
measles-mumps-rubella, polio, Bacillus Calmette-Guerin
(BCG) and Haemophilus influenza type B vaccine. In
Malaysia, HIV screening is performed only for pathogens
and infections associated with HIV including Mycobater-
ium tuberculosis, Cryptococcus species and syphilis but is
not routine.
Definitions of clinical syndromes and outcome
Meningitis was defined as cerebrospinal fluid (CSF)
pleocytosis (≥5 WBC/μL) plus two or more of the fol-
lowing: i) fever or history of fever (≥380C), ii) neck stiff-
ness, iii) headache, and was further classified as acute if
symptoms were present ≤ 7 days or chronic if longer.
Encephalitis was defined as encephalopathy (altered
level of consciousness, lethargy, irritability, and change
in behaviour or personality) longer than 24 h with two
or more of the following: i) fever or history of fever
(≥380C), ii) CSF pleocytosis (≥5 WBC/μL), iii) seizures
or focal neurological findings, iv) abnormal neuroimag-
ing consistent with encephalitis or v) abnormal electro-
encephalogram findings compatible with encephalitis.
Patients with neck stiffness and encephalitis were de-
fined as meningoencephalitis. A published consensus
case definition was used to classify TBM into confirmed,
probable and possible cases [10].
Criteria for exclusion were non-infectious CNS disor-
ders due to hypoxic, vascular, toxic and metabolic
causes, patients with CNS disorders lasting less than
24 h, and patients with malaria diagnosed on micros-
copy. Patients with an immune mediated post-infectious
aetiology such as acute disseminated encephalomyelitis
(ADEM) were enrolled as these often were associated
with a parainfectious aetiology. We used the modified
Rankin score (0 Asymptomatic, 1 Symptomatic; but no
significant disability, and able to carry out all usual activ-
ities and duties, 2 Mild disability; able to function with-
out assistance but unable to perform all previous
activities, 3 Moderate disability; walk without assistance
but needs help for some activities, 4 Moderately severe
disability; unable to walk without assistance and attend
to bodily functions, 5 Severe disability; bedridden and
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requiring constant care, 6 Death) to categorize the
neurological status of the study subjects at the time of
discharge from the hospital.
Laboratory and microbiological study procedure
Blood and CSF samples collected as part of clinical care
were used for routine and research investigations. Blood
was sent for bacterial cultures, malaria screening by mi-
croscopy, rapid plasma reagin (RPR) and HIV testing if
indicated as mentioned above. In addition to this, a con-
valescent blood, nasopharyngeal and throat swab, and
rectal swab were obtained if indicated. Routine CSF test-
ing involved (i) Gram stain for bacteria, (ii) Ziehl-
Nielsen stain for mycobacteria, (iii) India ink stain and
cryptococcal antigen for cryptococcus, (iv) bacterial cul-
ture, (v) glucose and total protein, and (vi) total and dif-
ferential white cell count. For suspected TBM cases, 1-
6 ml of CSF was sent for MTB PCR and/or culture at
the Sabah State Public Health Laboratory. Anti-NMDAR
antibodies were measured with a semi-quantitative indir-
ect fluorescent antibody method at a local laboratory.
CSF analysis for Japanese encephalitis IgM was per-
formed at the Malaysian National Public Health Labora-
tory at Sungai Buloh, Peninsular Malaysia.
Molecular testing procedures
A standardised and stratified approach was used with
first line testing on CSF samples using RT-PCR in a re-
search laboratory for viral pathogens as detailed in
Table 1. Negative results were followed by second line
testing using the MassCode (Agilent) platform.
In brief, nucleic acid from CSF was extracted using the
QIAmp Viral RNA mini kit. Complementary DNA syn-
thesis, PCR and purification of amplicons were done
using Agilent’s MassCode reagents. MassCode is a form
of multiplex PCR, which utilizes a ‘tag’ with a distinct
molecular mass conjugated directly to PCR primers [11].
Upon amplification of a pathogen sequence, these
masses are then incorporated into the resulting ampli-
cons. Masses are then cleaved off the amplicons and
identified via mass spectrometry. This methodology
allows for rapid and simultaneous screening against large
panels of known pathogens using minimal amount of
sample [12, 13]. The list of pathogens tested for using
this method are detailed in Table 1.
Statistical analysis
Patients were classified according to clinical syndrome
and the final aetiological diagnosis. Continuous variables
were summarized as medians and range and differences
between groups were analysed using Kruskal-Wallis test.
Categorical variables were summarized as numbers and
percentages and differences between groups compared
using chi-squared or Fisher’s exact test. All analyses were
performed using Stata version 12 (StataCorp, College
Station, Texas, USA). A two-sided value of p < 0.05 was
considered significant.
Ethics statement
The study was approved by the Medical Research Sub-
Committee of the Malaysian Ministry of Health (Refer-
ence NMRR-11-623-9629) and Menzies School of
Health Research, Australia (Reference 2011-1636). All
data were anonymised prior to analysis. Informed con-
sent was obtained from patients or available relatives if
their neurological condition did not allow them to. In-




There were 92 patients screened for the study and eight
were excluded with alternative diagnoses (1 septic en-
cephalopathy, one hypoxic encephalopathy, one cerebel-
lar tumour, two acute psychosis, one cerebrovascular
accident, one pneumonia, one suspected prion disease).
The median age was 32.5 (range 13–67) years, 60 (71 %)
were male, 15(18 %) HIV positive, and 55 (65 %) had no
significant past medical history. Of the HIV patients, 11
had CD4 counts of <50/ml, 1 had 50/ml, and three had
between 100–200/ml. Patients were from 18 of 23
districts in Sabah; 34/84 (40.5 %) were from the Kota
Table 1 Molecular Tests Conducted on CSF Samples
Viral pathogens Bacterial pathogens
First Level Tests Done for CSF samples (i) herpes simplex virus 1 and 2, (ii) varicella zoster
virus, (iii) enterovirus, (iv) Japanese encephalitis
virus, (v) dengue virus, (vi) nipah virus, (vii)
cytomegalovirus, (viii) West Nile virus, and (ix)
bunyavirus
Not Done
Second Level Test Done for CSF samples cytomegalovirus, Epstein Barr virus, La Crosse Virus,
mumps, varicella zoster virus, measles,, human
herpes virus 6, rabies, LCMV, California encephalitis
group (Bunyavirus), Human Alphavirus group
(Eastern, Western, Venezualan EEV), Bartonella,
Flavivirus group, Enterovirus group,, St. Louis
Encephalitis virus and West Nile Virus
Haemophilus influenza, Listeria monocytogenes,
Mycoplasma pneumoniae, Streptococcus
pneumoniae, Staphylococcus aureus, Streptococcus
agalactiae, Neisseria meningitis, Rickettsia,
Leptospira, Borrelia, Legionella pneumoniae,
Mycobacterium tuberculosis
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Kinabalu district and 63/84 (75 %) from the urban
West Coast Division of Sabah. 68/84 (81 %) patients
were Malaysian; with 22/84 (26.2 %) and 13/84
(15.5 %) from the majority Kadazan-Dusun and Bajau
ethnic groups respectively.
Clinical syndromes and aetiological diagnosis
Patients were categorized into the following clinical syn-
dromes; acute meningitis (n = 10: viral = 2, bacterial = 1,
fungal = 4, unidentified = 3), chronic meningitis (n = 9: all
Cryptococcus sp), meningoencephalitis (n = 12: viral = 1,
fungal = 1, parasitic = 1, neurosyphilis = 2, unidentified =
7), encephalitis (n = 12: viral = 2, parasitic = 3, auto-
immune encephalitis = 1, ADEM= 1, unidentified = 5),
confirmed tuberculous meningitis (n = 13), probable tu-
berculous meningitis (n = 20), and possible tuberculous
meningitis (n = 8) (Table 2). The demographic details,
vital signs, laboratory results and cerebrospinal fluid re-
sults of these patients are summarized in Table 2.
A confirmed aetiological diagnosis was made in 37 of
84 (44 %) patients, with Mycobacterium tuberculosis (13/
84, 15.5 %) the most common confirmed pathogen
(Table 3). In the 43 patients who did not have con-
firmed, probable or possible TBM, the following aetiol-
ogies were: viral (n = 5, (3 enterovirus, 1 Epstein Barr
virus, 1 Japanese encephalitis), bacterial (n = 1, Strepto-
coccus pneumonia), fungal (n = 14, all Cryptococcus spe-
cies), parasitic (n = 4, (3 Toxoplasma sp, 1 Naegleria
fowleri), neurosyphilis (n = 2), anti-NMDAR encephalitis
(n = 1) and acute disseminated encephalomyelitis
(ADEM) (n = 1), while 15 remained unidentified
(Table 3). No cases of herpes simplex virus meningitis or
encephalitis were diagnosed.
TBM was the clinical diagnosis in 41/84 (48.8 %) of
cases with CSF sent for MTB culture and PCR in 59 pa-
tients. Of those with clinical TBM, 13 of 41 (32 %) were
confirmed by MTB PCR and four of this 13 were add-
itionally MTB culture-positive (overall culture-positive
rate 4/41 (9.8 %); none were culture-positive but PCR







Encephalitis Meningoencephalitis P values
Number 41 10 9 12 12
Demographic results
Age; years, (median, range) 31 (13–64) 33 (15–65) 36.5 (22–67) 38 (16–57) 36 (14–62) p = 0.8
Males; (number, percentage) 31 (75.6 %) 6 (66.6 %) 7 (77.7 %) 9 (75 %) 6 (50 %) p = 0.4
Fever History (number, percentage) 32 (78 %) 9 (100 %) 7 (77.8 %) 10 (83.3 %) 8 (66.6 %) p = 0.4
Days of fever before presentation
(median, range)
14 (3–90) 3 (1–19) 35 (7–90) 5 (2–21) 4 (2–10) p < 0.001
Headache 33 (80.5 %) 8 (88.9 %) 8 (88.9 %) 8 (66.6 %) 7 (63.6 %) p = 0.6
Coma (GCS < 11) 12 (29.2 %) 2 (22.2 %) 0 (0 %) 4 (33.3 %) 3 (25 %) p = 0.4
HIV Positive (number, percentage) 4 (9.8 %) 3 (33.3 %) 4 (44.4 %) 2 (16.6 %) 3 (27.7 %) p = 0.3
Vitals signs and laboratory results
Pulse Rate; median (range), (beats/min) 85 (55–155) 101 (50–160) 88 (68–108) 101 (65–140) 99 (60–162) p = 0.2
Temperature; mean (range) (degrees Celsius) 37.8 (36–40) 38.5 (36.5–39) 37.6 (36.2–38.2) 38 (36.6–40.8) 36.8 (36.8–39.3) p = 0.4
White blood cell count; mean (range), ×103/μL 10.3 (4.3–25.3) 10.8 (6–30.3) 9.8 (4.3–13) 15.2 (4.1 to 24.9) 10 (4–22.2) p = 0.3
Hemoglobin; mean (range), (g/dl) 12.4 (8.1–16.8) 13.4 (7.4–15.9) 12.1 (8–16.4) 12 (8.2–15.9) 12.1 (8.8–15.3) p = 0.8
Platelet; mean (range), ×109/L 314 (83–582) 251 (86–296) 274 (212–443) 193 (58–767) 299 (61–470) p = 0.1
Lumbar Puncture Results
Opening Pressure (cm H2O) 21 (8–65) 6 (4–27) 17 (4–40) 15 (8–40) 15 (3–34) p = 0.2
Total White Cell Count 60 (0–1160) 95 (20–220) 40 (5–1050) 50 (8–615) 30 (0–305) p = 0.4
Neutrophil (Percentage) 5 (0–92) 20 (5–89) 30 (0–99) 10 (0–100) 4 (0–30) p = 0.09
>50 % Neutrophils (number, percentage) 7 (17.1 %) 2 (22.2 %) 3 (33.3 %) 5 (41.7 %) 6 (50 %) p = 0.04
Glucose (mmol/L) 2 (0.2-4.6) 3 (0.1-6) 1.7 (0.2-3) 3.8 (0.5-6.2) 4 (2-5) p = 0.7
CSF:blood glucose ratio 0.26 (0.09–0.51) 0.45 (0.05–0.87) 0.17 (0.1–0.31) 0.55 (0.06–0.83) 0.64 (0.32–0.8) p < 0.001
CSF:blood glucose ratio <50 %
(number, percentage)
37 (90.2) 5 (55.5) 8 (88.8) 4 (33.3) 2 (18.2) p = 0.03
Total Protein g/L 1.6 (0.3–7.1) 1.3 (0.5–4.2) 1.2 (0.7–3.8) 0.9 (0.4–8.3) 0.95 (0.3–1.6) p = 0.06
P < .05 by analysis of variance, the Kruskal-Wallis tests, χ2 test or Fisher’s exact test comparing the groups
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negative and no non-TBM patient was PCR or culture
positive for MTB. The remaining 18/41 (43.9 %) patients
had probable TBM and 11/41 (26.8 %) possible TBM
using the consensus case definition [10]. Four of 41
(9.8 %) patients with TBM had HIV and 37 (90.5 %) were
HIV negative and apparently immunocompetent
(Table 4).
Cryptococcal meningoencephalitis was the second
commonest CNS infection (14/84, 16.6 %) diagnosed
by cryptococcal antigen detection, with fungal culture
and speciation unavailable. In this group, 9/14 (64 %)
patients had HIV or other immunodeficiencies while
5 had no apparent immunodeficiency (Table 4). There
were two cases (2.4 %) of confirmed neurosyphilis,
three cases (3.6 %) of probable cerebral toxoplasmosis
in HIV patients, three patients with enterovirus infec-
tion and one case (1.2 %) each of confirmed Japanese
encephalitis (CSF Japanese encephalitis IgM positive)
and Epstein-Barr virus meningitis. There was a case
of probable primary amoebic meningoencephalitis
(PAM) due to Naegleria fowleri diagnosed by CSF wet
mount examination. Besides infectious aetiologies, we
diagnosed one case each of acute disseminated en-
cephalomyelitis (ADEM) and anti-N-methyl D-
aspartate receptor (anti-NMDAR) encephalitis. There
were 15 patients with no aetiological diagnosis after
initial microbiological testing and who did not have a
clinical diagnosis of TBM. In these patients, cerebro-
spinal fluid was available for extended molecular test-
ing, but no additional aetiological agent was
identified. The use of the MassCode platform did not
result in the detection of any new pathogen not pre-
viously diagnosed.
Outcome
The overall acute case fatality rate was 19 % (16/84) dur-
ing hospital admission. Additionally, 4 % (3/84), 15 %
(13/84) and 20 % (17/84) had severe, moderately severe,
or moderate neurological disability respectively on dis-
charge. Five percent (4/84) had slight or no significant
disability and 37 % (31/84) made a full recovery. The
duration of hospital stay was prolonged in all categories,
with a median of 28 days (range 4–59) in acute meningi-
tis, 33 days (range 22–80) for chronic meningitis, 22 days
(range 12-72) for encephalitis and 24 days (range 1-280)
for confirmed, probable and possible tuberculous
meningitis.
The outcome from TBM was significantly worse than
non-tuberculous causes, with respective mortality rates
of 29 % (12/41) versus 9 % (4/43) (p = 0.02), and severe
or moderately-severe neurological deficits of 27 %
(11/41) versus 11 % (5/43) (p = 0.04). All TBM pa-
tients received corticosteroids and anti-tubercular
medications. In TBM patients, there was no signifi-
cant difference in the median time to start of specific
anti-tubercular medication in the patients who died
or were severely disabled (2.5 days (range 0–4)) com-
pared to those who had a good outcome (2 days
(range 1–3)). In the TBM patients who died, nine
were within 30 days; eight from presumed hydroceph-
alus and extensive cerebral infarctions, and one from
multiple tuberculomas with brainstem herniation,
while 3 others expired at 52, 63 and 140 days after
Table 3 Classification and causes of CNS infections
Aetiology Total (%)
Infectious Cause n=67 (80%)
Mycobacterium tuberculosis
(Confirmed, probable and possible)
41 (50 %)
Cryptococcus sp 14 (15 %)
Treponema pallidum 2 (2 %)
Toxoplasma gondii 3 (4 %)
Japanese Encephalitis virus 1 (1 %)
Epstein–Barr virus 1 (1 %)
Naegleria fowleri 1 (1 %)
Enterovirus 3
Streptococcus pneumoniae 1
Immune-mediated cause n = 2 (2 %)
ADEM 1 (1 %)
NMDAR Encephalitis 1 (1 %)
Unidentified n = 15 (23 %)
Total n = 84
Table 4 Causes of CNS infections in immunocompetent versus
immunocompromised patients
Aetiology Immunocompetenta
n = 64 (76 %)
Immunocompromisedb






Cryptococcus sp 5 9 14







Epstein–Barr virus 1 - 1
Naegleria fowleri 1 - 1




Unidentified 12 3 15
aIncludes cases for whom immune status was unknown
bReasons for immunocompromised status: 15 HIV positive; 3 on steroid
therapy; 1 post bone marrow transplant; 1 post splenectomy
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admission. In patients with cryptococcal meningitis,
14 % (2/14) patients had a fatal outcome while 21 %
(3/14) were severely disabled. In the 15 patients with-
out TBM and no aetiological agent identified, there
were two deaths (13.3 %), while 12 (80 %) made a full
or good recovery. The other two patients with a fatal
outcome included one with Japanese encephalitis and
another with HIV and toxoplasmosis.
Discussion
In this prospective study of adult CNS infection in a ter-
tiary hospital in Kota Kinabalu, Sabah, East Malaysia, an
aetiological diagnosis was confirmed in 44 % of patients.
Whether classified according to clinical syndrome or a
confirmed aetiology, tuberculous meningitis (TBM) was
the most common diagnosis, accounting for almost 50 %
of CNS infections. Compared to other diagnoses, TBM
was associated with a significantly higher proportion of
death and severe neurological disability. TB is well-
recognized as a major problem in East Malaysia, but
rates of drug resistance and HIV in the community are
fortunately low [14, 15]. For all categories of central ner-
vous system infections, the duration of hospital stay was
also fairly long, probably reflecting the time for neuro-
logical sequelae to resolve or stabilize. The aetiological
agents identified in this study contrast with those previ-
ously described in developed countries including Eng-
land, USA and France, where viral infections and
autoimmune encephalitis were the major diagnoses
[1–3]. These differences may not be surprising due to
geographic, climatic and economic differences. How-
ever, our results also differ compared to studies con-
ducted from the South and East Asian countries of
Nepal and Vietnam [4–6], highlighting the importance
of local data.
The diagnosis of TBM remains challenging despite
availability of new diagnostic tools [16]. In this cohort,
only 32 % of patients clinically classified as TBM accord-
ing to a consensus criteria had a microbiological diagno-
sis. All were confirmed by MTB PCR with a smaller
proportion also culture-positive, while no patient had
CSF acid-fast bacilli observed by microscopy using the
Ziehl-Neelsen stain. These and other published results
suggest novel diagnostic methods with increased sensi-
tivity are required to further improve the diagnosis of
TBM [16]. Over half of TB meningitis patients had ei-
ther a fatal outcome or severe neurological deficits des-
pite institution of anti-tubercular therapy and steroids; a
finding similar to other studies [17]. A recent large well-
powered study of intensified dose rifampicin for TBM
did not result in an improvement in outcome [18], and
adjunctive agents will be required to improve the poor
outcome.
Cryptococcal sp. was the major cause of CNS infection
in immunocompromised patients (Table 4), emphasising
the importance of testing for Cryptococcus in this group
using serum/CSF cryptococcal antigen and/or Indian
ink. However, 5/14 patients diagnosed with cryptococcal
meningoencephalitis were immunocompetent. Crypto-
coccus gatti and Cryptococcus neoformans var grubii
CNS infections are well-recognized in apparently im-
munocompetent hosts and have been reported in
Vietnam and Malaysia [19–21]. However local microbio-
logical facilities were not able to differentiate the crypto-
coccal species and we did not comprehensively exclude
obscure forms of immunosuppression. We speculate that
some of these cases were likely to be Cryptococcus gatti.
This has clinical importance since longer treatment
durations of up to 18 months and worse neurological
outcomes are reported in Cryptococcus gatti infections
[19, 20]. Similar to previous studies, cryptococcal
meningitis was associated with a poor outcome with
approximately one third of diagnosed patients dead or
disabled.
In non-TB, non-cryptococcal meningitis, the propor-
tion of microbiologically confirmed diagnoses was low.
Only one patient had a bacterial pathogen isolated
from CSF by culture, which may be due to the high
rate of outpatient antibiotic use. Bacterial PCR may be
more sensitive in detecting pathogens after antibiotic
use, but no additional bacterial pathogens were de-
tected using this, and more studies are needed to fur-
ther evaluate the utility in this setting. The availability
of viral PCR allowed us to confirm a viral diagnosis in
several patients. Finally, clinicians need to be aware of
rare but serious causes of CNS infection and inflam-
mation in Sabah, Malaysia. Identification of single pa-
tients with ADEM, anti-NMDAR encephalitis and
primary amoebic meningoencephalitis highlight the
broad spectrum of aetiologies requiring consideration.
This is of more than academic importance as the
treatment strategies are radically different. The pa-
tients with ADEM and anti-NMDAR encephalitis were
managed by immunomodulation using steroids in the
former, and intravenous immunoglobulins and steroids
in the latter. The patient with amoebic meningo-
encephalitis survived after receiving a combination of
amphotericin B, fluconazole and rifampicin. Despite
the use of modern molecular methods, almost 60 per
cent of the aetiological agents responsible for central
nervous infections in our study remained unidentified.
This is comparable to previously-mentioned studies
conducted in England, France, USA and Vietnam.
However, non-identification of a confirmed pathogen
was not associated with increased mortality compared
to TBM or the fatality rates observed in the aforemen-
tioned studies.
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Conclusion
Tuberculous meningitis was the most common diagnosis
in a prospective study of CNS infections in an adult ter-
tiary hospital in Sabah, East Malaysia, and was associ-
ated with high rates of death and severe neurological
disability. Central nervous system involvement is the
most serious complication of Mycobacterium tubercu-
losis infection, and further research is required to im-
prove the diagnosis and outcome of this devastating
disease.
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